CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TREM2MEDS focuses on developing a gene therapy for Alzheimer's Disease and Nasu-Hakola Disease by engineering hematopoietic stem cells to express the TREM2 protein. This approach aims to restore microglial function, reduce neuroinflammation, and prevent amyloid-beta accumulation, ultimately transitioning to human clini…
TREM2MEDS emerges from the ERC PoC 2022 project TREM2μENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimer’s Disease (AD) and Nasu-Hakola Disease (NHD) in murine models.
A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to microglia dysfunction contributing to and/or causing the onset and manifestations of AD and NHD.
TREM2MEDS approach involves the transplantation of hematop…
UNIVERSITA DEGLI STUDI DI PADOVA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
UMG INSTITUTE OF MOLECULAR GENETICS ACA SCIEN CZECH REPU
Czechia, Praha 4
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
